These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32638047)

  • 21. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
    Outani H; Tanaka T; Wakamatsu T; Imura Y; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2014 Jun; 14():455. PubMed ID: 24946937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
    Kumar R; Knick VB; Rudolph SK; Johnson JH; Crosby RM; Crouthamel MC; Hopper TM; Miller CG; Harrington LE; Onori JA; Mullin RJ; Gilmer TM; Truesdale AT; Epperly AH; Boloor A; Stafford JA; Luttrell DK; Cheung M
    Mol Cancer Ther; 2007 Jul; 6(7):2012-21. PubMed ID: 17620431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone acetyltransferase 1 up regulates Bcl2L12 expression in nasopharyngeal cancer cells.
    Miao BP; Zhang RS; Yang G; Sun JJ; Tang YY; Liang WF; Liu T; Wen Z; Yang PC; Nie GH
    Arch Biochem Biophys; 2018 May; 646():72-79. PubMed ID: 29621521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-377 exerts a potent suppressive role in osteosarcoma through the involvement of the histone acetyltransferase 1-mediated Wnt axis.
    Xia P; Gu R; Zhang W; Shao L; Li F; Wu C; Sun Y
    J Cell Physiol; 2019 Dec; 234(12):22787-22798. PubMed ID: 31152456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone acetyltransferase 1 is a succinyltransferase for histones and non-histones and promotes tumorigenesis.
    Yang G; Yuan Y; Yuan H; Wang J; Yun H; Geng Y; Zhao M; Li L; Weng Y; Liu Z; Feng J; Bu Y; Liu L; Wang B; Zhang X
    EMBO Rep; 2021 Feb; 22(2):e50967. PubMed ID: 33372411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.
    Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2010 Sep; 37(3):605-14. PubMed ID: 20664929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib: Clinical development of a potent anti-angiogenic drug.
    Schutz FA; Choueiri TK; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma.
    Jin X; Tian S; Li P
    Oncol Res; 2017 Jul; 25(6):939-946. PubMed ID: 27938492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells.
    Garcia N; Al-Hendy A; Baracat EC; Carvalho KC; Yang Q
    Cells; 2020 Dec; 10(1):. PubMed ID: 33396427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
    Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
    Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin induces cross-regulation between autophagy and apoptosis in uterine leiomyosarcoma cells.
    Li B; Takeda T; Tsuiji K; Wong TF; Tadakawa M; Kondo A; Nagase S; Yaegashi N
    Int J Gynecol Cancer; 2013 Jun; 23(5):803-8. PubMed ID: 23532091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
    Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
    Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
    Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
    J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1.
    Hayashi T; Horiuchi A; Sano K; Yaegashi N; Konishi I
    Anticancer Res; 2015 Sep; 35(9):4665-79. PubMed ID: 26254356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
    Reguera-Nuñez E; Man S; Xu P; Kerbel RS
    Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    de Almeida BC; Dos Anjos LG; Uno M; Cunha IWD; Soares FA; Baiocchi G; Baracat EC; Carvalho KC
    Cells; 2019 Nov; 8(11):. PubMed ID: 31744257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
    Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
    Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.